Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases

Simone Cowan, Suzanne Morin, Pierre Ernst

Osteoporosis is a well known consequence of glucocorticoid treatment that can result in significant morbidity and mortality. Glucocorticoid-induced bone loss occurs early, usually within 6–12 months of starting therapy. During this time the rate of bone loss is rapid before decreasing, usually within 6–12 months of starting therapy. Clinically this decrease in bone mineral density puts patients at an increased risk of fracture. Specifically, with a decline in bone mass of one standard deviation below the mean for young adults, the risk of fracture doubles. Characteristically, glucocorticoid-induced osteopenia and osteoporosis occur at a faster rate in trabecular bone; consequently, the ribs and vertebrae are common sites of fracture, although hip fractures have also been reported. As long term treatment with oral glucocorticoids is a common practice in the management of patients with chronic respiratory diseases, strategies to decrease the burden of glucocorticoid-induced osteoporosis are needed.}

Glucocorticoid-induced bone loss results from a decrease in bone formation due to reduced intestinal calcium absorption, increased urinary calcium excretion, and reduced osteoblast formation and function. The bisphosphonates, a class of drugs structurally similar to pyrophosphate, alter the bone remodelling process. By binding to hydroxyapatite these agents structurally inhibit osteoclastic activity and prevent bone resorption. This significantly increases bone mineral density in the lumbar spine and femur and decreases the rate of fracture at these sites. For this reason, bisphosphonates such as etidronate and alendronate have received official approval for the treatment and prevention of postmenopausal osteoporosis in many countries. The bisphosphonates have also been studied in the prevention and treatment of glucocorticoid-induced osteoporosis.

In this issue of Thorax Pitt et al shed further light on the use of etidronate for the treatment of glucocorticoid-induced osteoporosis. Using a double blind, placebo controlled design, patients receiving oral glucocorticoids for at least six months were randomised to receive etidronate 400 mg daily or placebo for 14 days followed by 76 days of calcium and vitamin D supplementation. This three month cycle was repeated eight times over a two year period. In the primary measure of outcome a significant difference between etidronate and placebo was found in the mean percentage change from baseline in the lumbar spine after two years. Specifically, after six months there was a mean increase of 4.33% in the bone mineral density of the lumbar spine for the etidronate group which increased to 5.12% at two years. In contrast, no clinically important changes were reported in patients receiving placebo.

A particular strength of this clinical study is that it represents one of the few trials using a randomised, double blind, placebo controlled design to show the efficacy of a bisphosphonate in glucocorticoid-induced osteoporosis for a study population consisting largely of patients with chronic respiratory disease, mainly asthma. Previous investigations have been conducted predominantly in patients with rheumatoid arthritis where the absolute risk of bone loss may be unique due to additive effects from the underlying disease process and differences in the cumulative glucocorticoid dose. Moreover, epidemiological studies enrolling patients with respiratory diseases to assess the use of etidronate in glucocorticoid-induced osteoporosis have used non-randomised or unblinded designs, short follow up periods, and historical controls. By demonstrating the usefulness of etidronate for treating glucocorticoid-induced osteoporosis, Pitt et al have confirmed the results of this preliminary research.

Unfortunately, the study by Pitt et al lacked sufficient power to translate the primary efficacy measure of bone mineral density into a clinical measure of effectiveness such as a decrease in the rate of fracture. These investigators were also unable to find significant treatment differences in bone mineral density of the trochanter or femoral neck, as in a previous study of glucocorticoid-induced osteoporosis.

It is noteworthy that 60.9% and 47.5% of the screened population in the study by Pitt et al met the WHO definition for osteoporosis of the hip and spine, respectively. This finding underlines the necessity for preventive therapies. The bisphosphonates have also shown favourable results in the prevention of glucocorticoid-induced osteoporosis. Diamond et al reported that cyclical etidronate prevented glucocorticoid-induced bone loss of the lumbar spine and femoral neck in postmenopausal women commencing glucocorticoids for the first time or recommencing therapy. In a recent double blind, placebo controlled trial by Adachi et al, a significant difference in the mean percentage change from baseline in the bone mineral density of the lumbar spine (3.72%) and trochanter (4.14%) was detected between patients randomised to receive cyclical etidronate or placebo. Patients recently starting treatment with glucocorticoids maintained their bone mineral density of the lumbar spine and trochanter when randomised to receive preventive therapy with etidronate; in contrast, those in the placebo group experienced a 3.23% and 2.74% decrease from baseline, respectively. Furthermore, significantly fewer postmenopausal women receiving etidronate sustained vertebral fractures.

Other bisphosphonates have also been studied for use in the prevention of glucocorticoid-induced osteoporosis. In the combined results of two 48 week, multinational, randomised, double blind trials, alendronate significantly increased the bone mineral density of the spine and hip relative to baseline and placebo. Moreover, in postmenopausal women a lower incidence of vertebral fractures occurred with alendronate. Additionally, alendronate has been investigated for the prevention of glucocorticoid-induced osteoporosis in patients with sarcoidosis by Gonelli et al who found a significant difference from placebo in the mean percentage change from baseline in the bone mineral density of patients randomised to receive alendronate. Lastly, intravenous pamidronate has shown promising results in preventing bone loss in patients initiating glucocorticoid therapy.

The next question to be answered is whether any particular oral bisphosphonate is truly safer and more effective in preventing and treating glucocorticoid-induced osteoporosis. Until the publication of larger clinical trials with longer follow up periods the answer to this question
will remain unclear. Both etidronate and alendronate have now been shown to decrease vertebral fractures in postmenopausal women being treated with glucocorticoids.20,21 In terms of safety, as a class, bisphosphonates are generally well tolerated. Alendronate has been associated with oesophagitis and oesophageal ulcers in a small percentage of patients, particularly if not taken according to the manufacturer’s recommendations.22 Bone histomorphometry was found to be normal in patients treated with both continuous alendronate24 and intermittent cyclical etidronate.25 Currently, etidronate has received approval in Britain for the treatment and prevention of glucocorticoid-induced osteoporosis; therefore, pending the publication of results from ongoing alendronate studies, it would be prudent to use intermittent etidronate therapy for this indication.

It is suggested that a preventive strategy be adopted for all patients with respiratory disease initiating chronic oral glucocorticoids; this strategy should also be applied to patients already receiving chronic oral glucocorticoids with the goal of preventing further bone loss. Consensus guidelines have been published for the prevention and treatment of glucocorticoid-induced osteoporosis26; however, in view of the aforementioned new information and the criticism received for some of these recommendations,27–31 we propose the following strategy. Firstly, known and potential risk factors for osteoporosis should be modified—this includes maximising the use of inhaled glucocorticoids in asthma, using the lowest possible dose of the oral glucocorticoid, initiating exercise and smoking cessation programmes, and ensuring the appropriate intake of calcium and vitamin D. Secondly, baseline bone mineral density of the lumbar spine should be measured in all high risk patients, preferably using dual energy x-ray absorptiometry. This measurement will serve to monitor the efficacy of the preventive strategy. Thirdly, postmenopausal women should be offered hormone replacement therapy first as it may confer cardiovascular benefits in addition to its protective effect on bone. When hormone replacement therapy is contraindicated or deemed undesirable, alendronate or intermittent cyclical etidronate should be considered. Lastly, in men and premenopausal women in whom hypogonadism is present, it should be corrected first and intermittent cyclical etidronate should then be considered. However, it is still unclear how long these patients should be treated with a bisphosphonate, particularly premenopausal women. Furthermore, the potential risk to the fetus must be considered in women of childbearing potential.

In conclusion, osteoporosis and its resulting fractures are deleterious consequences of glucocorticoid therapy. As these medications have become a mainstay in the pharmacotherapy of several respiratory diseases, the primary prevention of bone loss in high risk patients is warranted. With the emergence of clinical studies demonstrating the usefulness of the bisphosphonates for increasing and preserving bone density and preventing vertebral fractures, clinicians are now well equipped to reduce the morbidity associated with glucocorticoid-induced osteoporosis in patients with respiratory diseases.

SIMONE COWAN

Respiratory Epidemiology Unit, Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec H3A 1A3, Canada

PIERRE ERNST

Division of Respiratory Medicine, McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada